Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513204 | 0.91 | PTGDR (0.79) | PTGDR | |
| SCHEMBL4492174 | 0.90 | PTGDR (1.00) | PTGDR | |
| SCHEMBL4506638 | 0.89 | PTGDR (1.00) | PTGDR | |
| SCHEMBL4504463 | 0.89 | PTGDR (0.84) | PTGDR | |
| SCHEMBL4513534 | 0.89 | PTGDR (0.77) | PTGDR | |
| SCHEMBL4503850 | 0.85 | PTGDR (0.79) | PTGDR | |
| SCHEMBL4957274 | 0.84 | PTGDR (0.76) | PTGDR | |
| SCHEMBL4498447 | 0.82 | PTGDR (0.73) | PTGDR | |
| SCHEMBL4505164 | 0.82 | PTGDR (0.76) | PTGDR | |
| SCHEMBL4506725 | 0.81 | PTGDR (0.83) | PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | claimed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | claimed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | claimed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1954831-B1 | AHR MEDIATOR | SYMRISE AG (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1954831-A2 | AHR MEDIATOR | Symrise GmbH & Co. KG (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2005037239-A2 | USE OF A COMPOUND FROM THE GROUP OF HETERODIAZOLES OR A SALT OF SAID COMPOUND, COSMETIC OR THERAPEUTIC FORMULATION CONTAINING SAID COMPOUND OR SALT, SAID COMPOUND OR SALT AS A THERAPEUTIC AGENT, AND SAID SALT | SYMRISE GMBH & CO. KG (DE) | 2005-04-28 | — | — | WO | disclosed |
| EP-1326955-B1 | MULTI-PHASE SOAP | SYMRISE GMBH & CO KG (DE) | 2004-12-22 | — | — | EP | disclosed |
| EP-1421853-A1 | Insect repellent composition | Beiersdorf AG (DE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1326955-A1 | MULTI-PHASE SOAP | HAARMANN & REIMER GMBH (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002024857-A1 | MULTI-PHASE SOAP | HAARMANN & REIMER GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| EP-0995424-A2 | Deodorant combinations of anti-adhesion compounds (ceramides and sphingosine derivatives) and microbicides | Beiersdorf Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | disclosed |
| EP-0995425-A2 | Deodorant combinations of anti-adhesion compounds (sterol and sterol derivatives) and microbicides | Beiersdorf Aktiengesellschaft (DE) | 2000-04-26 | — | — | EP | disclosed |
| EP-0985408-A2 | Combination of antiadhesives (carbohydrates) and microbicides | Beiersdorf Aktiengesellschaft (DE) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.